SCHEMBL24028007

SCHEMBL24028007

Cc1cccc(C)c1-c1cc(C=O)c(Cl)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 2/20 0.37
ERN1 O75460 2/20 0.35
TRIM24 O15164 1/20 0.34
TRIM33 Q9UPN9 1/20 0.34
PTPN11 Q06124 1/20 0.33
GRIA1 P42261 1/20 0.33
CACNG8 Q8WXS5 1/20 0.33
CYP1A2 P05177 2/20 0.33
CYP1A1 P04798 1/20 0.33
MYC P01106 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PTGS1 P23219 3/20 0.31
PTGS2 P35354 3/20 0.31
PKM P14618 1/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30212834 0.79 ALDH1A1 (0.47) ALDH1A1TSHRTDP1ERN1CYP1A2
SCHEMBL24027895 0.79 ALDH1A1 (0.47) ALDH1A1TSHRTDP1ERN1CYP1A2
SCHEMBL1053001 0.73 TDP1 (0.50) ALDH1A1TSHRTDP1ERN1MEN1
SCHEMBL12577688 0.73 ERN1 (0.43) ALDH1A1TSHRTDP1ERN1
SCHEMBL2021441 0.72 PTGER4 (0.38) ALDH1A1TSHRERN1MYCSMN1; SMN2
SCHEMBL15803551 0.72 ALDH1A1 (0.42) ALDH1A1TSHRERN1TRIM24TRIM33
SCHEMBL24028384 0.72 MAPK14 (0.40) MYCMEN1KMT2APTGS1PTGS2
SCHEMBL4966498 0.72 TDP1 (0.37) ALDH1A1TDP1ERN1MEN1KMT2A
SCHEMBL30255462 0.72 ALDH1A1 (0.40) ALDH1A1TSHRTDP1ERN1GRIA1
SCHEMBL3936518 0.71 ALDH1A1 (0.50) ALDH1A1TSHRTDP1ERN1TRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-06-08 US disclosed
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD. (IL) 2023-06-08 US disclosed
WO-2021229571-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF METABOMED LTD (IL) 2021-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174507-A1 IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF ACSS2, ADSS2, GLS2 ALDH1A1 210/4885TSHR 3698/4885TDP1 3284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.